Sponser
DZOMO
Principal Investigator
Abstract
Establishing a Genomic Signature For Aggressive Prostate Cancer in Men From Kenya to Inform population Specific Treatment Strategies
Background
Prostate cancer is the most commonly diagnosed cancer and leading cause of cancer-related deaths amongst men globally. The management of prostate cancer has changed over the last two decades. However, there is paucity of data on individual genetic determinants and role of environmental factors in influencing tumour progression and treatment outcomes especially in patients presenting with aggressive prostate cancer.
Broad Objective
Identify the genetic factors (gene variants and pathways) that drive aggressive prostate cancer in Kenyan men, with the goal to establishing genetic subtypes that could lead to novel curative therapies.
Study Design
A prospective Case Only Study
Study Setting
KNH and Upper Hill Medical Centre
Methodology
Eligible 100 men patients presenting with aggressive PCa symptoms (age-matched with controls) will be administered a questionnaire to capture their demographics, risk factors and have their blood samples (20mls) and tissue biopsies taken for PSA comparison and DNA extraction and sequencing at Garvan Institute of Medical Research (GIMR, collaborating institution) to identify genetic signatures predisposing to aggressive prostate cancer in relation to environmental factors in a given geographic locations. Two-well-trained Research Assistants will be responsible for data collection and entry in Kenya using the data collection form. De-identified data will be shared between the sites via the central i-DZOMO database, which will be housed at the Garvan Institute of Medical Research (GIMR). The databases will be used for further analyses and local training in statistical analyses provided under the leadership of the GIMR team.
